share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A：其他
美股SEC公告 ·  2024/09/09 15:37

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a company listed in the United States, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, made pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are not preliminary and no filing fee is required. This step is typically part of the company's preparations for upcoming shareholder meetings, where various corporate matters are voted upon. The materials filed are intended to provide additional information to shareholders beyond what was included in the original proxy statement.
ZyVersa Therapeutics, Inc., a company listed in the United States, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, made pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are not preliminary and no filing fee is required. This step is typically part of the company's preparations for upcoming shareholder meetings, where various corporate matters are voted upon. The materials filed are intended to provide additional information to shareholders beyond what was included in the original proxy statement.
在美国上市的ZyVersa Therapeutics, Inc.公司已向美国证券交易委员会（SEC）提交了确切的附加材料，作为其代理声明程序的一部分。根据1934年证券交易法第14(a)节的规定，提交的文件表明这些材料不是初步资料，不需要提交费用。这一步骤通常是公司准备即将举行的股东大会的一部分，在该会议上将对各种公司事务进行投票。提交的材料旨在向股东提供超出原始代理声明中所包含信息的补充资料。
在美国上市的ZyVersa Therapeutics, Inc.公司已向美国证券交易委员会（SEC）提交了确切的附加材料，作为其代理声明程序的一部分。根据1934年证券交易法第14(a)节的规定，提交的文件表明这些材料不是初步资料，不需要提交费用。这一步骤通常是公司准备即将举行的股东大会的一部分，在该会议上将对各种公司事务进行投票。提交的材料旨在向股东提供超出原始代理声明中所包含信息的补充资料。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。